Pneumococcal capsular polysaccharide antigens (11-valent) (PCV11 antigens)

Pneumococcal capsular polysaccharide antigens are the primary virulence factors of Streptococcus pneumoniae, consisting of complex carbohydrate polymers that encapsulate the bacterium and shield it from host phagocytosis [1]. In an 11-valent presentation, these antigens represent a specific subset of serotypes—typically 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F—selected for their high contribution to the global burden of invasive pneumococcal disease [2]. These polysaccharides function as T-cell independent antigens, but when conjugated to carrier proteins in vaccines, they elicit a T-cell dependent immune response characterized by high-affinity IgG production and immunological memory [3]. The therapeutic objective of targeting these antigens is to induce serotype-specific antibodies that facilitate opsonophagocytosis, thereby preventing diseases such as pneumonia, meningitis, and bacteremia [4]. While 11-valent formulations were historically significant in clinical development, they paved the way for current higher-valency conjugate vaccines that provide broader protection against the diverse landscape of pneumococcal serotypes [2]. Sources: [1] NIH/PMC7150172; [2] CDC Pink Book; [3] PubMed 15103000; [4] WHO Vaccine Standardization.

Other names

Streptococcus pneumoniae capsular polysaccharides11-valent pneumococcal vaccine antigensPCV11 polysaccharidesPneumococcal capsular polysaccharides

Induction of serotype-specific humoral immunity through the production of IgG antibodies that facilitate opsonophagocytosis and bacterial clearance [1, 4].